Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Elizabeth, McCaffrey"'
Autor:
Chinthaka B. Samaranayake, Elizabeth McCaffrey, John Coucher, Margot Lehman, G. Tao Mai, Michelle A. Murphy
Publikováno v:
ERJ Open Research, Vol 6, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/87651ba37f0549ff8d135269f0def44b
Autor:
Michelle Murphy, Chinthaka B Samaranayake, Elizabeth McCaffrey, G. Tao Mai, Margot Lehman, John Coucher
Publikováno v:
ERJ Open Research
ERJ Open Research, Vol 6, Iss 1 (2020)
ERJ Open Research, Vol 6, Iss 1 (2020)
Nivolumab, a human IgG4 anti-PD1 monoclonal antibody, has been shown to have promising results in patients with advanced non-small cell lung cancer (NSCLC) [1, 2]. Despite the improved outcomes compared to chemotherapy, only ∼20% of patients had a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::310c9e561f31240fc746c650116ff82c
http://europepmc.org/articles/PMC7061202
http://europepmc.org/articles/PMC7061202
Autor:
Euan Walpole, Alexandria C McGrath, Elizabeth McCaffrey, Samantha A. Hollingworth, Geeta Sandhu
Publikováno v:
Anti-Cancer Drugs. 29:786-790
Erlotinib is used to treat non-small-cell lung cancer (NSCLC). Erlotinib was subsidized on the Pharmaceutical Benefits Schedule in Australia for the treatment of advanced stage (IIIB or IV) NSCLC (August 2008). In the pivotal trial supporting initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2825005cf5bb3cb8f6d4f3f6a3c59669
https://doi.org/10.1097/cad.0000000000000640
https://doi.org/10.1097/cad.0000000000000640
Publikováno v:
Lung Cancer.
Aim: Pre-clinical studies have shown radiotherapy augmenting efficacy of immunotherapy in NSCLC, however the clinical benefits are yet to be defined. This study aims to determine the effects of previous radiotherapy on outcomes of nivolumab in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21e373f24516f8df7d622d56af02a7b1
https://doi.org/10.1183/13993003.congress-2018.pa2219
https://doi.org/10.1183/13993003.congress-2018.pa2219
Autor:
Sophie Feng, Jermaine Coward, Paul Kalokerinos, Kenneth J. O'Byrne, Elizabeth McCaffrey, John Coucher
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 12(11)
The use of immune checkpoint inhibitor (ICI) therapy in the treatment of solid organ malignancies is becoming increasingly common. This has prompted the recognition of a new class of immune related adverse effects (irAEs) which stem from the upregula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e3d3bc72f5970790b8e4f91ee1ef2f6
https://pubmed.ncbi.nlm.nih.gov/28843363
https://pubmed.ncbi.nlm.nih.gov/28843363
Publikováno v:
Clinical nuclear medicine. 42(6)
The omentum is a rare metastatic site for prostatic adenocarcinoma. We present a case of metastatic castrate-resistant prostate cancer, with progressive omentum invasive prostate cancer identified on prostate-specific membrane antigen (PSMA) PET/CT s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::554670162ace6ed567e151e1c4bfa716
https://pubmed.ncbi.nlm.nih.gov/28240670
https://pubmed.ncbi.nlm.nih.gov/28240670
Autor:
Gang Tao Mai, Dannie Zarate, Hon Trinh, Margot Lehman, Mark B. Pinkham, Elizabeth McCaffrey, Margaret McGrath, Margaret Dauth, Keith Horwood
Publikováno v:
The Clinical Respiratory Journal. 10:428-434
Background and Aim: Thoracic radiotherapy administered concurrently with chemotherapy is the standard of care for patients with inoperable stage III non-small cell lung cancer, but the optimal chemotherapy regimen is not clearly established. The obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e09d46931d8fa7b296e899c591ce67b
https://doi.org/10.1111/crj.12233
https://doi.org/10.1111/crj.12233
Autor:
Elizabeth McCaffrey, Natacha Sorour, Alessandra Francesconi, Jasotha Sanmugarajah, Peter J Gilbar, Ian McPherson
Publikováno v:
Breast Cancer Management. 3:9-11
A LETTER IN RESPONSE TO: Lakhanpal R, Stuart-Harris R, Chan A et al. Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required. Breast Cancer Manage. 2(5), 367–374 (2013).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3749d918628b9b4fb5ea4208ba45645
https://doi.org/10.2217/bmt.13.76
https://doi.org/10.2217/bmt.13.76
Autor:
Hon, Trinh, Mark Blayne, Pinkham, Margot, Lehman, Dannie, Zarate, Margaret, Dauth, Margaret, McGrath, Elizabeth, McCaffrey, Gang Tao, Mai, Keith, Horwood
Publikováno v:
The clinical respiratory journal. 10(4)
Thoracic radiotherapy administered concurrently with chemotherapy is the standard of care for patients with inoperable stage III non-small cell lung cancer, but the optimal chemotherapy regimen is not clearly established. The objective of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0b365e13df4251587c77f0be18cdb35e
https://pubmed.ncbi.nlm.nih.gov/25353367
https://pubmed.ncbi.nlm.nih.gov/25353367
Publikováno v:
Industrial Law Journal. 25:144-148
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e8ed57e7386d71e8a9d7da94c29e34
https://doi.org/10.1093/ilj/25.2.144
https://doi.org/10.1093/ilj/25.2.144